Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00011986 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
A Phase 3 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,312
- Enrollment target
NCT00011986: Completed Phase 3 study, sponsored by Gynecologic Oncology Group.
NCT00011986 is a Phase 3 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 4,312 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (459% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00011986, a Phase 3 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,312 participants
- Enrollment target
Study Summary
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is most effective in treating ovarian epithelial cancer and peritoneal cancer. Randomized phase III trial to compare the effectiveness of various combination chemotherapy regimens in treating patients who have stage III or stage IV ovarian cancer or primary peritoneal cancer.
Primary Outcome
Proportion of participants whose overall survival exceeded 5 years.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Gemcitabine Hydrochloride
- DRUG Topotecan Hydrochloride
- DRUG Pegylated Liposomal Doxorubicin Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,312 participants |
| Start Date | 2001-01 |
| Est. Completion | 2013-01-28 |
| Phase | Phase 3 |
What the finished NCT00011986 record still lists
NCT00011986 is an interventional study that assigns participants to a tested intervention. Its 4,312 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (459% higher).
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT00011986 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00011986 about?
NCT00011986 is a clinical study titled "Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer". Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is most effective in treating ovarian epithelial cancer and peritoneal cancer. Randomized phase III trial to compare the effectivene...
What is the current status of trial NCT00011986?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,312 participants. The study started on 2001-01. Estimated completion is 2013-01-28.
What interventions are being tested in trial NCT00011986?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Gemcitabine Hydrochloride (DRUG), Topotecan Hydrochloride (DRUG), Pegylated Liposomal Doxorubicin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00011986?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00011986's enrollment target sits among peer trials
4,312 57th of 2000 higher than 1,944 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05774951 · 4,300 participants · Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
- NCT05543616 · 4,292 participants · Phase 2
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
- NCT05910567 · 4,346 participants · NA
A Research Study of Abdominal Ultrasound (FAST) in Children With Blunt Torso Trauma
- NCT07044297 · 4,390 participants · Phase 3
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia